Posts

Pharma & Veterinary Briefing 2026: FDA Green Book Exclusivities, Advanced Manufacturing, and Key IP Decisions

Image
Quick 2-minute reading Pharma Regulatory & IP Digest: Veterinary Drug Exclusivities, Distributed Manufacturing, and Landmark D.C. Circuit Patent Ruling Welcome to the Sidvim LifeSciences monthly briefing. This month, we cover key developments in the 2026 veterinary drug market, new USFDA manufacturing proposals, an impactful PBM lawsuit settlement, and a critical appellate decision regarding post-trial ANDA modifications. 1. USFDA Green Book 2026: A Deep Dive into Veterinary Drug Exclusivities The veterinary medicine sector has seen approximately 16 animal drug approvals so far in 2026, encompassing 6 New Chemical Entities (NCEs) and 10 Lifecycle Management (LCM) expansions . While human pharmaceutical data packages follow Section 505 of the FD&C Act, the legal architecture for animal health is governed strictly by Section 512 and administered by the Centre for Veterinary Medicine (CVM) . The framework breaks down into two core exclusivity shields for New Animal Drug Applicat...
Read more

1.) June ANDA Approvals, Formulation Tech and 2.) CAFC Patent Decisions: Why the Federal Circuit Invalidated Enanta’s Protease Inhibitor Patent Against Pfizer

Image
Two minutes read Pharma Regulatory & IP Digest: June 2026 ANDA Approvals, Tech-Driven Formulations, and Landmark Federal Circuit Ruling Welcome to the Sidvim LifeSciences monthly briefing. This month, we cover key US FDA generic approvals, evolving formulation technology trends, and a major Federal Circuit patent decision on priority documentation. 1. USFDA ANDA Approvals Dashboard (June 2026) In June 2026, the USFDA granted 94 ANDA approvals , which included 11 tentative approvals . Tentative approvals indicate that a generic formulation meets all scientific and quality benchmarks but is held back from immediate commercial rollout due to unexpired patent terms or market exclusivities held by the innovator . The leading generic developers securing approvals during this period include: Alembic: 6 approvals Aurobindo & MSN: 5 approvals each Apotex, Micro Labs, Mylan, Teva, & Zydus: 4 approvals each Amneal & Macleods: 3 approvals each Concord Biotech, Sun Pha...
Location: Mumbai, Maharashtra, India
Read more